Targeting loss of heterozygosity for cancer-specific immunotherapy

Developing therapeutic agents with potent antitumor activity that spare normal tissues remains a significant challenge. Clonal loss of heterozygosity (LOH) is a widespread and irreversible genetic alteration that is exquisitely specific to cancer cells. We hypothesized that LOH events can be therape...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Michael S., Mog, Brian J., Douglass, Jacqueline, Pearlman, Alexander H., Hsiue, Emily Han-Chung, Paul, Suman, DiNapoli, Sarah R., Konig, Maximilian F., Pardoll, Drew M., Gabelli, Sandra B., Bettegowda, Chetan, Papadopoulos, Nickolas, Vogelstein, Bert, Zhou, Shibin, Kinzler, Kenneth W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2021
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000272/
https://www.ncbi.nlm.nih.gov/pubmed/33731480
http://dx.doi.org/10.1073/pnas.2022410118

Ejemplares similares

Ejemplares similares